Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 2Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Solid Tumor, Adult 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Tiragolumab × Clear all
NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
4 enrolled
Tumor-Agnostic

Neoplasms

NCT03708224 2025-01-28

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of California, San Francisco

Phase 2 Recruiting
55 enrolled
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT05259319 2023-10-17

IMMUNOs-SBRT

Centre Georges Francois Leclerc

Phase 1 Unknown
92 enrolled
GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡